News
FDA approves Kamada's IV drug Glassia as 4th US augmentation therapy for Alpha-1
Israeli biopharmaceutical company Kamada Inc. has been granted approval by the US Food and Drug Administration for Glassia, its intravenous augmentation therapy to treat emphysema due to Alpha-1 Antitrypsin Deficiency.
Alpha-1 Antitrypsin Deficiency, or Alpha-1, is the most important known genetic risk factor for emphysema.
Glassia is the fourth IV augmentation drug marketed in the United States. It comes in liquid form and is the first augmentation therapy to require no mixing.
As part of its preparations to market the drug in the United States, the company has set up a US subsidiary called Kamada Inc.
